A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors

Trial Profile

A Study of ARRY-382 in Combination With Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients With Advanced Solid Tumors

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 13 Nov 2017

At a glance

  • Drugs ARRY 382 (Primary) ; Pembrolizumab (Primary)
  • Indications Breast cancer; Colorectal cancer; Gastric cancer; Malignant melanoma; Non-small cell lung cancer; Ovarian cancer; Pancreatic cancer; Solid tumours
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 13 Nov 2017 The Phase 1b part of the study has been completed (n=19). The enrollment has been initiated for phase 2 part of the trial. In the phase 2 cohort, both melanoma and non-small cell lung cancer patients are enrolled and plans to include pancreatic cancer patients.
    • 13 Nov 2017 According to an Array BioPharma media release, data was presented at the Society for Immunotherapy of Cancer (SITC) Annual Meeting held in Nov 2017.
    • 13 Nov 2017 Results published in the Array BioPharma media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top